0.4151
price up icon2.29%   0.0093
after-market After Hours: .42 0.0049 +1.18%
loading
Alx Oncology Holdings Inc stock is traded at $0.4151, with a volume of 375.35K. It is up +2.29% in the last 24 hours and down -14.50% over the past month. ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$0.4058
Open:
$0.425
24h Volume:
375.35K
Relative Volume:
0.80
Market Cap:
$28.53M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.1398
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
-9.70%
1M Performance:
-14.50%
6M Performance:
-74.99%
1Y Performance:
-93.12%
1-Day Range:
Value
$0.4102
$0.4436
1-Week Range:
Value
$0.404
$0.4887
52-Week Range:
Value
$0.404
$8.78

Alx Oncology Holdings Inc Stock (ALXO) Company Profile

Name
Name
Alx Oncology Holdings Inc
Name
Phone
650-466-7125
Name
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
Employee
65
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
ALXO's Discussions on Twitter

Compare ALXO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALXO
Alx Oncology Holdings Inc
0.4151 28.53M 0 -151.16M -130.08M -2.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.20 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
525.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.09 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.22 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.07 28.51B 3.81B -644.79M -669.77M -6.24

Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-06-25 Upgrade Jefferies Hold → Buy
Dec-19-24 Downgrade Jefferies Buy → Hold
Mar-08-24 Downgrade Stifel Buy → Hold
Dec-08-23 Upgrade Jefferies Hold → Buy
Dec-22-21 Downgrade Jefferies Buy → Hold
Sep-30-21 Initiated Stifel Buy
May-05-21 Resumed Credit Suisse Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Apr-06-21 Initiated UBS Buy
Feb-10-21 Initiated H.C. Wainwright Buy
Aug-11-20 Initiated Cantor Fitzgerald Overweight
Aug-11-20 Initiated Credit Suisse Outperform
Aug-11-20 Initiated Jefferies Buy
Aug-11-20 Initiated Piper Sandler Overweight
View All

Alx Oncology Holdings Inc Stock (ALXO) Latest News

pulisher
Jun 16, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Jun 16, 2025
pulisher
Jun 12, 2025

ALX Oncology Confirms Directors at Annual Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

ALX Oncology reports annual meeting results By Investing.com - Investing.com Nigeria

Jun 12, 2025
pulisher
Jun 12, 2025

ALX Oncology reports annual meeting results - Investing.com

Jun 12, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Weighs in on ALX Oncology FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 07, 2025

ALX Oncology (NASDAQ:ALXO) Downgraded to “Sell” Rating by Wall Street Zen - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Nuveen Asset Management LLC Has $275,000 Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Acquired by Two Sigma Investments LP - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Bank of America Corp DE Grows Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Acquired by Deutsche Bank AG - Defense World

Jun 03, 2025
pulisher
May 31, 2025

Northern Trust Corp Acquires 23,324 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World

May 31, 2025
pulisher
May 30, 2025

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference | ALXO Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

ALX Oncology Management to Showcase Novel Cancer Treatment Advances at Major Jefferies Healthcare Conference - Stock Titan

May 30, 2025
pulisher
May 27, 2025

D. E. Shaw & Co. Inc. Decreases Stock Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World

May 27, 2025
pulisher
May 27, 2025

H.C. Wainwright maintains ALX Oncology stock Buy rating By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

H.C. Wainwright maintains ALX Oncology stock Buy rating - Investing.com

May 27, 2025
pulisher
May 24, 2025

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO) - The Globe and Mail

May 24, 2025
pulisher
May 23, 2025

UBS Group Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World

May 23, 2025
pulisher
May 22, 2025

Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews

May 22, 2025
pulisher
May 22, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

May 22, 2025
pulisher
May 21, 2025

ALXO: UBS Maintains 'Buy' Rating, Lowers Price Target | ALXO Sto - GuruFocus

May 21, 2025
pulisher
May 21, 2025

ALXO: UBS Maintains 'Buy' Rating, Lowers Price Target | ALXO Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

UBS Adjusts Price Target on ALX Oncology Holdings to $1 From $1.20, Maintains Buy Rating - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

ALX Oncology presents preclinical data, plans for ALX-2004 - BioWorld MedTech

May 21, 2025
pulisher
May 21, 2025

UBS Adjusts Price Target for ALX Oncology (ALXO) to $1 | ALXO St - GuruFocus

May 21, 2025
pulisher
May 21, 2025

UBS Adjusts Price Target for ALX Oncology (ALXO) to $1 | ALXO Stock News - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Transcript : ALX Oncology Holdings Inc.Special Call - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

ALX Oncology : Investor Presentation ALX2004 Webcast May 20 2025 Final (2a4ce1) - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

ALX Oncology Holdings Inc. Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

ALXO Unveils Advanced Antibody-Drug Conjugate ALX2004 for Tumor Treatment | ALXO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

ALX Oncology Highlights Differentiated Design, Preclinical - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

First-in-Class Cancer Drug: ALX Oncology's Novel EGFR-ADC Gets FDA Green Light for Clinical Trials - Stock Titan

May 20, 2025
pulisher
May 20, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Cubist Systematic Strategies LLC - Defense World

May 20, 2025
pulisher
May 13, 2025

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EG - GuruFocus

May 13, 2025
pulisher
May 13, 2025

ALX Oncology to Host R&D Webcast Event Highlighting its - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - Stock Titan

May 13, 2025
pulisher
May 11, 2025

HC Wainwright Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World

May 11, 2025
pulisher
May 09, 2025

ALXO Stock: HC Wainwright & Co. Lowers Price Target | ALXO Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

ALX Oncology Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

ALXO Advances Cancer Therapy Focus and Pipeline Development | AL - GuruFocus

May 08, 2025
pulisher
May 08, 2025

ALXO Advances Cancer Therapy Focus and Pipeline Development | ALXO Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

ALX ONCOLOGY Earnings Results: $ALXO Reports Quarterly Earnings - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Financial Health Check: Examining Alx Oncology Holdings Inc (ALXO)’s Key Ratios - DWinneX

May 08, 2025
pulisher
May 08, 2025

ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025
pulisher
May 06, 2025

ALX Oncology to Report First Quarter 2025 Financial Results on M - GuruFocus

May 06, 2025
pulisher
May 05, 2025

ALX Oncology Holdings Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 02, 2025

Will ALXO Make A Comeback In July? - RTTNews

May 02, 2025
pulisher
May 02, 2025

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times

May 02, 2025
pulisher
May 02, 2025

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | ALXO Stock News - GuruFocus

May 02, 2025

Alx Oncology Holdings Inc Stock (ALXO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Alx Oncology Holdings Inc Stock (ALXO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Pons Jaume
PRESIDENT & CSO
Feb 19 '25
Sale
1.15
1,326
1,525
579,388
Lettmann Jason
CHIEF EXECUTIVE OFFICER
Feb 19 '25
Sale
1.15
2,159
2,483
170,270
Pinto Shelly
Interim CFO
Jan 06 '25
Sale
1.80
2,221
3,998
87,902
Pinto Shelly
Interim CFO
Dec 30 '24
Sale
1.58
1,426
2,253
90,123
Pons Jaume
PRESIDENT & CSO
Dec 30 '24
Sale
1.58
10,796
17,060
580,714
Hemrajani Rekha
Director
Dec 02 '24
Buy
1.55
30,000
46,404
33,000
Pinto Shelly
SVP, FINANCE AND CAO
Aug 14 '24
Sale
2.58
564
1,455
91,549
Randolph Sophia
CHIEF MEDICAL OFFICER
Aug 14 '24
Sale
2.58
1,365
3,522
325,711
Pons Jaume
PRESIDENT & CSO
Aug 14 '24
Sale
2.58
1,937
4,997
591,510
Pons Jaume
PRESIDENT & CSO
Jul 11 '24
Option Exercise
0.99
20,000
19,800
613,447
$20.66
price up icon 0.78%
$36.03
price up icon 0.45%
$21.28
price up icon 3.30%
$100.64
price up icon 1.16%
$106.47
price down icon 0.23%
biotechnology ONC
$242.07
price up icon 0.36%
Cap:     |  Volume (24h):